GLP1R and type 2 diabetes mellitus: A six-month treatment with exenatide, a short-acting GLP-1R agonists, was evaluated in a longitudinal study on 10 overweight/obese patients with PWS—3 patients were affected by T2D—showing a reduction in appetite scores and an improvement in HbA1c, with no changes in weight or BMI [100].